Evaluation of serum soluble HLA-G levels post-recovery from COVID-19 and post-vaccination (Sinopharm and Pfizer-BioNTech)

• Published in: Human immunology Vol. 84; no. 2; pp. 71 - 74
• Main Authors: Hamed, Roaa M., Mahmood, Majid M., Ad'hiah, Ali H.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2023; American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc
• Subjects: COVID-19; HLA-G Antigens; Humans; Pfizer-BioNTech; Recovery; Short Communication; Sinopharm; Soluble HLA-G; COVID-19; Sinopharm; Pfizer-BioNTech; Soluble HLA-G; Recovery
• ISSN: 0198-8859; 1879-1166
• DOI: 10.1016/j.humimm.2022.11.002

Serum soluble HLA-G (sHLA-G) levels have been shown to be upregulated in COVID-19 patients. In this study, sHLA-G levels were examined in COVID-19 patients 14–21 days post-recovery (100 patients) and 80 uninfected controls. In addition, individuals vaccinated with Sinopharm or Pfizer-BioNTech (50 individuals each) were followed 21 days post-first dose and 21 days post-second dose. Serum sHLA-G levels were significantly higher in recovered patients than in controls. The first and second doses of Sinopharm and Pfizer-BioNTech were associated with significantly elevated levels of sHLA-G compared to controls or recovered patients, except for the first dose of Pfizer-BioNTech where sHLA-G levels did not show significant differences compared to recovered patients. In conclusion, recovery from COVID-19, as well as vaccination with two doses of Sinopharm or Pfizer-BioNTech, were associated with up-regulated levels of sHLA-G molecules, but the first dose of Sinopharm had the greatest effect in raising sHLA-G levels.